The Scaleup Europe Fund: Navigating Late Stage Growth Capital Opportunities for European HealthTech and MedTech Companies

Nelson Advisors
51 minutes ago
11 min read

Strategic Genesis: Combatting the European Tech Exodus in Life Sciences

Despite Europe's thriving startup ecosystem, which consistently produces world-class scientific discoveries and breakthrough technologies, innovative enterprises face severe challenges when attempting to scale within the continent. As tech and life science companies transition from early-stage validation to the capital-intensive scaleup phase, they routinely encounter an underdeveloped late-stage venture capital sector. This domestic funding gap, particularly acute in growth rounds approaching or exceeding nine figures, has historically forced many of Europe's most promising innovators to seek capital from foreign institutional investors, often relocating their headquarters, executive talent, and intellectual property to the United States or Asia.

This capital flight represents a systemic drain on European economic value and technological sovereignty. The vulnerability of European innovation is underscored by high-profile foreign acquisitions of pioneering technology firms. Notable examples include Advanced Micro Devices acquiring the Finnish artificial intelligence company Silo AI for $665 Million in 2024, and IonQ's purchase of the UK-based quantum computing firm Oxford Ionics for more than $1 Billion in 2025.

To curb this trend and foster domestic alternatives, European policymakers have designed the Scaleup Europe Fund as a concrete deliverable of the European Commission's Competitiveness Compass and a direct response to the Draghi Report's urgent call to close Europe's deep-tech financing gap.

Operating as a key pillar of the EU Startup and Scaleup Strategy, the Scaleup Europe Fund is designed to serve as a strategic autonomy tool. Implemented with the support of the European Investment Bank, the fund acts as a catalyst to mobilise private and public institutional capital, ensuring that the critical technologies of the next decade remain anchored in Europe.

For healthtech, medtech and biotechnology companies, sectors characterised by highly capital-intensive development timelines, prolonged clinical trials, and stringent regulatory processes, this fund represents a transformative shift in the European funding landscape.

Core Architecture: Fund Size, Structure and Private Governance

The Scaleup Europe Fund is positioned to become Europe's largest technology growth fund, targeting €5 Billion in total commitments. To achieve global parity and effectively compete with the massive venture funds of the US and China, the European Commission has signaled intentions to scale the fund's total capacity to €25 Billion over time.

The core capital structure is a public-private hybrid. The European Commission has committed €1 Billion to the fund, sourced directly from Horizon Europe, the EU's flagship research and innovation programme. The remaining €4 Billion is being raised from private and sovereign institutional investors, with private partners having already committed €1.5 Billion by the end of 2025.

Following a highly competitive public call for expressions of interest launched between December 2025 and February 2026, the European Innovation Council Fund Board shortlisted elite management firms from Sweden, the UK, and France to oversee the vehicle. This shortlist included EQT and Northzone from Sweden, Eurazeo from France, and Atomico and Vitruvian Partners from the United Kingdom. In May 2026, Swedish investment firm EQT was appointed as the preferred adviser and fund manager. EQT operates as an independent, market-based manager, ensuring that investment decisions are commercially driven and free from political influence.

Furthermore, EQT commits a significant portion of its own capital to the fund, establishing a profit-making framework that aligns public policy objectives with private sector returns.

Structurally, the Scaleup Europe Fund will operate as a separate compartment within the existing EIC Fund umbrella. This architecture allows the fund to deploy significantly larger investment tickets than previous European funding mechanisms. While the EIC Fund historically capped its equity investments at €30 Million, the Scaleup Europe Fund will focus on direct equity investments in the range of €100 Million and above. This capability is designed to lead or co-lead major financing rounds, helping European innovators scale into "unicorns" without relinquishing operational control to foreign buyers.

Strategic Alignment: Positioning Healthtech, Medtech and Biotech for Scale

For healthtech, medtech, and biotechnology scaleups, the launch of the fund, scheduled to execute its first investments in autumn 2026, addresses the financial mismatch inherent in scaling life science technologies. Healthcare innovation requires patient, long-term growth capital to finance multi-centre Phase II/III clinical trials, secure global regulatory approvals (such as CE-MDR and FDA clearances) and construct advanced, compliant manufacturing facilities. The availability of €100 Million+ investment tickets provides the financial runway required to navigate these hurdles.

The composition of the fund’s founding investors provides portfolio companies with strategic benefits that extend far beyond capital injection.

Founding Investor Group	Institutional Members	Strategic Value to Healthtech & Medtech Scaleups
Life Sciences Specialists	Novo Holdings	Brings unmatched clinical, commercial, and industrial expertise, with a deep understanding of biotechnology development and global drug distribution networks.
Sovereign & Promotional Banks	EIFO (Denmark), Wallenberg Investments (Sweden), BGK (Poland)	Provides stable, long-term backing linked to national and European industrial strategies, facilitating local regulatory navigation and commercial procurement within regional health systems.
Pension & Asset Managers	APG Asset Management (representing Dutch pension fund ABP), Allianz (German Insurer)	Represents vast pools of non-dilutive, patient capital capable of supporting successive growth rounds and stabilizing long-term corporate valuation.
Commercial Banking Networks	Santander/Mouro Capital, Intesa Sanpaolo	Offers access to cross-border financial services, debt facilities, corporate banking, and established corporate healthcare networks across Europe.
Philanthropic Foundations	Fondazione Compagnia di San Paolo, Fondazione Cariplo	Bridges the gap to clinical research institutions, university hospital networks, and public health initiatives aligned with broader societal and UN development goals.

The management of the fund will actively leverage EQT's specialised internal divisions, particularly its dedicated Life Sciences, Ventures, and Growth teams. This cross-disciplinary expertise is essential for modern healthtech companies, which frequently operate at the intersection of biology, software, and advanced engineering.

By connecting scaleups with EQT's global network of clinical advisors, hospital executives, and industrial partners, the fund helps portfolio companies accelerate commercialisation, optimise supply chains and secure market entry across multiple European jurisdictions.

Comparative Framework: Navigating the Multi-Tiered European Growth Capital Ecosystem

To navigate the expanding European funding landscape, healthcare executives must understand the distinct operational roles of the EIC Accelerator, the EIC STEP Scale Up call, and the Scaleup Europe Fund. Each mechanism represents a different level of maturity, funding capacity, and qualification requirements.

Feature / Metric	EIC Accelerator	EIC STEP Scale Up Call	Scaleup Europe Fund (SEF)
Target Technology Maturity	TRL 6 to 8 (Technology demonstrated in relevant environments)	Late-stage development & rapid scaling of strategic tech	Series B & C commercial scaling, global deployment, and market expansion
Primary Financial Instruments	Blended finance: up to €2.5M in grants and €0.5M to €10M (or up to €15M) in equity	Equity-only investments	Direct equity and quasi-equity growth capital
Funding Amount (Ticket Size)	Max €2.5M grant; equity capped typically at €10M–€15M	€10 million to €30 million	€100 million and above
Institutional Scale	Under the main EIC Fund umbrella	Part of the EIC STEP call within the 2026 Work Programme	Independent, privately managed compartment under EQT
Evaluation Framework	Standard EIC multi-stage process with quarterly cutoff dates	Quarterly batching system for rigorous strategic and financial proposals	Direct application to the fund manager (EQT) utilizing commercial private market due diligence
Co-investment Requirements	Evaluates risk; crowding in private capital is desired but not rigidly benchmarked at entry	Strictly enforces the "20% Rule" pre-commitment from a qualified lead investor	Market-driven, leading or co-leading major, syndicated European investment rounds

To ensure application readiness, corporate planning must align with the specific batching and evaluation timelines established under the EIC 2026 Work Programme. The cut-off dates for both early-stage Accelerator proposals and the mid-tier STEP Scale-Up program are highly structured, requiring significant lead times for preparation.

Evaluation Cycle (2026)	EIC Accelerator Step 2 Cut-off Dates	EIC STEP Scale-Up Cut-off Dates
First Batch / Q1	January 7, 2026	February 11, 2026
Second Batch / Q2	March 4, 2026	May 6, 2026
Third Batch / Q3	May 6, 2026	September 9, 2026
Fourth Batch / Q4	July 8, 2026	November 25, 2026
Fifth Batch / Q5	September 2, 2026	No corresponding cut-off in Q5
Sixth Batch / Q6	November 4, 2026	No corresponding cut-off in Q6

Geographic Compliance, UK Exclusion and Swiss Bilateral Frameworks

As a concrete delivery of European strategic autonomy, the Scaleup Europe Fund mandates that funded companies retain the majority of their value creation, including intellectual property, manufacturing capabilities and headquarter functions, within the European Union or Horizon Europe associated countries.

This geopolitical positioning has significant strategic and operational implications for healthtech and medtech companies located in non-EU-27 jurisdictions, specifically within the United Kingdom and Switzerland.

The United Kingdom: Complete Equity Exclusion and Corporate Redomiciling

The post-Brexit relationship between the United Kingdom and the European Union creates a restrictive operational environment for British healthtech and medtech enterprises. While the UK’s formal association with Horizon Europe allows British SMEs and research consortiums to participate in research centric grants, such as the EIC Pathfinder and EIC Transition initiatives, it explicitly excludes them from accessing any equity or investment components.

Consequently, UK-domiciled startups are eligible to apply for the grant portion of the EIC Accelerator (up to €2.5 Million for TRL 6-8 development), but they are completely ineligible for the EIC STEP Scale-Up call and the Scaleup Europe Fund.

For high-growth British healthtech scaleups seeking to access these multi-million-euro equity pools, the only viable pathway is to execute a corporate restructure, effectively establishing a primary operating headquarters and transferring key intellectual property to an eligible EU Member State or Associated Country prior to submitting a full application.

Switzerland: Bilateral Pathways and Strict Compliance Audits

In contrast to the UK, Switzerland's active participation as an Associated Country to Horizon Europe allows Swiss-domiciled startups and "small mid-caps" (up to 499 employees) to qualify for late-stage equity initiatives, including the Scaleup Europe Fund. However, Swiss healthtech scaleups must navigate a rigorous, multi-layered compliance audit to demonstrate their strategic alignment with the broader European ecosystem. Swiss companies cannot pitch their solutions solely within the context of their domestic market.

Instead, they must explicitly show how their technologies, manufacturing pipelines, and clinical data structures strengthen European industrial sovereignty and security of supply, particularly for products on the Union list of critical medicines. Furthermore, Swiss applicants must present a funded, executable plan detailing how they will establish or scale physical operations, clinical testing sites, or commercial distribution centres within EU Member States within 12 months of receiving the investment.

Executive Playbook: Qualification Benchmarks and Pre-Commitment Rules

For healthtech and medtech executives preparing to apply for the Scaleup Europe Fund or the mid-tier EIC STEP program, operational planning must begin six to twelve months in advance. Because the fund is overseen by EQT alongside highly analytical institutional investors, the diligence process focuses heavily on financial discipline, commercial scalability, and regulatory compliance.

Operational and Financial Benchmarks

To qualify for these late-stage growth vehicles, a healthtech company must demonstrate robust commercial traction. While early-stage grants focus primarily on scientific novelty, the Scaleup Europe Fund and its precursors target scaleups with established product-market fit.

The fund typically targets enterprises with annual revenues ranging between €2 Million and €15 Million, with a proven, audited year-over-year growth rate exceeding 25% for at least two consecutive fiscal years.

For the EIC STEP Scale-Up program, the commercial benchmarks are even higher, requiring an Annual Recurring Revenue (ARR) of over €10 Million and gross margins exceeding 40%. Although current profitability is not a strict requirement, the application must include an investor-grade, five-year financial model outlining a credible path to EBITDA breakeven within three to four years post-investment.

The Pre-Commitment Mandate and the "20% Rule"

A critical hurdle for healthtech scaleups is the "20% Rule" pre-commitment requirement mandated under the EIC STEP Scale-Up framework. Companies cannot apply for these public-private growth equity tickets in a vacuum. To secure a €10 Million to €30 Million ticket, the applicant must have already obtained a formal, legally backed commitment from a qualified private lead investor. This lead investor must commit to funding at least 20% of the total target round.

Furthermore, the total funding round must be three to five times the size of the requested EU equity ticket. For example, if a medical device scaleup requests a €20 Million equity ticket from the EIC, it must target a total funding round of €60 Million to €100 Million, with a private lead investor committing at least €12 Million to €20 Million. This mechanism ensures that public capital acts as a cornerstone to catalyze larger private co-investments, de-risking the round and accelerating market deployment.

Data Sovereignty and Regulatory Auditing

Because the fund serves as a strategic autonomy tool, healthtech scaleups must ensure that their technical and regulatory frameworks align with European standards. This is particularly critical for digital health and artificial intelligence companies, where compliance with the EU AI Act and GDPR must be integrated directly into the product design.

Investee companies are expected to host their infrastructure on European servers, minimise dependencies on non-EU cloud hyperscalers to mitigate vendor lock-in, and maintain absolute, unencumbered ownership of their core software codebase, patented clinical algorithms, and proprietary medical data.

Conclusions and Strategic Recommendations for Board-Level Decision-Makers

The establishment of the Scaleup Europe Fund represents a significant evolution in the European Union’s approach to venture capital and industrial planning. By partnering with an experienced global manager like EQT and securing anchor commitments from major institutional investors like Novo Holdings and Allianz, the European Commission is shifting from grant-based, fragmented funding toward a market-driven growth equity model.

This structural change provides healthtech, medtech, and biotech scaleups with the large-scale, long-term capital required to build global healthcare leaders without having to leave the European ecosystem.

For healthtech and medtech boards of directors, the emergence of this multi-billion-euro funding architecture requires immediate, proactive adjustments to corporate finance and operational strategies:

Sovereignty-by-Design in Corporate Structuring: Healthtech scaleups, particularly those based in the UK, must evaluate their long-term corporate geography. If late-stage capital requirements exceed €50 million, boards should consider establishing an operational headquarters, transferring intellectual property, or redomiciling to an eligible EU Member State or Associated Country. Similarly, Swiss entities must structure their growth plans to include rapid, measurable expansion of operations, manufacturing, or clinical sites inside the EU-27 borders.
Alignment with Life Science Anchor Backers: Healthcare scaleups should tailor their business models to align with the strategic goals of the fund's founding partners. Positioning technologies to align with the investment criteria of life science specialists like Novo Holdings, or ensuring compatibility with the long-term pension goals of APG/ABP, can significantly improve a company's prospects during the due diligence process.
Accelerating Investor Readiness: Scaleup executives should initiate comprehensive pre-audit processes to ensure their financial reporting, beneficial ownership records, and data architectures meet institutional standards. Preparing five-year financial models that demonstrate a clear, audited path to EBITDA breakeven within three to four years is essential to withstand the rigorous due diligence of independent managers like EQT.
Securing Qualified Lead Investors: Because the EIC STEP Scale-Up program and the broader fund rely on co-investment structures, companies must build relationships with qualified private lead investors well ahead of application deadlines. Securing a firm commitment for at least 20% of the target round from a private lead investor is a necessary first step to unlock public matching equity.

By implementing these strategic preparations, healthtech and medtech enterprises can position themselves to successfully leverage the Scaleup Europe Fund, turning Europe's boldest venture capital initiative into a launchpad for global healthcare leadership.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech